eli lilly retatrutide study Lilly's triple agonist hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Novo Duopoly Seeking Differentiation Through a Triple
Pay in 4 interest-free payments of $7.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30

























